SERA

Sera Prognostics, Inc. [SERA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SERA Stock Summary

Top 10 Correlated ETFs

SERA

Top 10 Correlated Stocks

SERA

In the News

SERA Financial details

Company Rating
-
Market Cap
303.88M
Income
-35.49M
Revenue
306K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-4.36
Forward P/E
-
PEG
2.15
P/S
493.79
P/B
2.16
P/C
-
P/FCF
-5.83
Quick Ratio
3.42
Current Ratio
3.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.14
EPS next Y
-
EPS next Q
-
EPS this Y
-18.88%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
11.6%
Revenue last 5Y
53.42%
Revenue Q/Q
-2.38%
EPS Q/Q
8.7%
-
-
-
-
SMA20
-24.78%
SMA50
-50.47%
SMA100
-39.71%
Inst Own
-
Inst Trans
-
ROA
-41%
ROE
-43%
ROC
-0.54%
Gross Margin
26%
Oper. Margin
-12543%
Profit Margin
-11320%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.52-11.32
52W High
-60.73%
52W Low
+332%
RSI
40.23
Rel Volume
0.64
Avg Volume
236.8K
Volume
152.36K
Perf Week
3.1%
Perf Month
-33.44%
Perf Quarter
-40.82%
Perf Half Y
-40.41%
-
-
-
-
Beta
1.494
-
-
Volatility
0.07%, 0.88%
Prev Close
4.1%
Price
4.32
Change
2.86%

Something similar

Top by Market Cap
AMZN
NVDA
VTI
TL0.DE
AAPL
Top Correlated ETFs
MOAT
ZHU.TO
MDEV
MOTE
GLL
Top Correlated Stocks
LCUT
PINC
NSSC
TNXP
IPSI
Similar Market Cap
BLUE.PA
M1GU.SI
0M6I.L
OTB.L
WTI

Company Profile

Healthcare Medical - Diagnostics & Research
  • Volume Average 236.8K
  • Market Capitalization 303.88M
  • Employee 55
  • CEO Ms. Evguenia Lindgardt M.B.A.
  • Headquarters Salt Lake City,UT,US
  • IPO Date 2021-07-15
  • Website https://seraprognostics.com

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.